Figure 3From: Randomized controlled trial of toremifene 120 mg compared with exemestane 25 mg after prior treatment with a non-steroidal aromatase inhibitor in postmenopausal women with hormone receptor-positive metastatic breast cancer Subgroup analyses of consistent results for clinical benefit; There were no statistical significant differences. Back to article page